About to go live #HBRat100. Looking forward to an energizing conversation about the future of business and Novartis's important role in the next generation of health. Thanks for having me, Harvard Business Review.

The heart of our company is our science. Today’s news builds on our longstanding commitment to improving and extending the lives of breast cancer patients. I couldn’t be prouder of our teams working on this medicine.

With the strong Q1 results we shared today, I’m extremely proud of how Novartis has started 2023. Our strong start to the year and confidence in our growth drivers allow us to raise our full-year guidance.

Highlighted by a positive Phase 3 readout in early breast cancer, our pipeline momentum gives us confidence in our growth outlook. More on our Q1 results and the strong growth Novartis delivered to start 2023: bit.ly/3N6gy8O

I spent part of my early career in malaria clinics across Africa and continue to be passionate about creating a malaria-free world. As we marked #WorldMalariaDay this week, I wanted to share the history of this ancient scourge and perspectives for the way forward:

I want to encourage Harvard University alumni in my network to vote in the #Harvard elections before they close this week. I couldn’t be prouder my wife Srishti Gupta Narasimhan has been nominated for the Board of Overseers—a testament to her leadership and commitment to education. Voting

It was great to sit down with the team at Yahoo Finance to talk about some of the exciting news in oncology at Novartis and what our renewed strategy means for our pipeline of innovative medicines. Thanks for having me, Julie Hyman Anjalee Khemlani Brad Smith.

So much of the power of science is realized through community—through the ways we share research, come together around tough scientific challenges, and work together to tackle diseases like cancers.  Proud to have joined our Novartis teams at ASCO, where we shared strong and

IgA nephropathy is a devastating disease, mostly affecting young adults, that could lead to dialysis or kidney transplantation. We’re excited by the opportunity to address this healthcare challenge, with the potential to bring additional, much-needed treatment options to

Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off. #NovartisNews $NVS $NOVN #NVSQ223

These trial results bring us one step closer to a potential first-in-class treatment for patients living with CSU. Thank you to all those involved in this study.

Our Beacon of Hope summer fellowship students met CEO Vas Narasimhan and had the chance to ask him questions and share their experiences at Novartis labs. We look forward to continuing to support students from Historically Black Medical Schools and break down #DEI barriers.

Today’s announcement is another promising step forward on our journey to reimagine medicine for and with patients around the world.

Novartis delivered a very strong quarter, with double-digit sales and core operating income growth leading to a further upgrade to 2023 guidance. #NovartisNews $NVS $NOVN #NVSQ323

Novartis is entering its new era as a focused medicines company from a position of strength. Today, I’m proud to share our very strong results for Q3. Read more from Novartis here: novartis.com/news/media-rel…

Great to talk with @JimCramer yesterday morning about what Novartis’ renewed strategy has meant for our business performance and the strength of our pipeline of innovative medicines. #JPM24

On the latest episode of The David M. Rubenstein Show: Peer-to-Peer Conversations, I had the chance to speak with David about my career and leadership journey and all I’ve learned along the way. I hope you’ll watch the episode here: youtu.be/t8ifgEIbgvg?si…